Integrating Seamlessly Into the NHS CRC Pathway

Oricol™ PreView is designed to integrate seamlessly into the existing NHS colorectal cancer (CRC) diagnostic pathway, enabling earlier assessment, faster decision-making, and more efficient patient flow. Origin Sciences is the only company to have conducted an interventional study within the NHS Community Diagnostic Centre (CDC) model, positioning the Triomic Study as a significant milestone for demonstrating real-world deployment at scale.

Enhancing Efficiency Within the CDC Environment

By operating directly within the established NHS CDC framework, OriCol™ PreView supports improvements in pathway efficiency and service delivery. The approach has already demonstrated clear operational and clinical benefit:

  • Referral to specialist wait times reduced from approximately 35 days to just 5 days
  • Generation of robust, real-world NHS operating cost data for OriCol™ PreView.
  • Strong evidence of patient acceptability, deployment feasibility, and pathway optimisation.
  • Publishable health-economic insights supporting in the UK and replication across European healthcare systems.

These findings highlight how minimally invasive, community-delivered diagnostics can meaningly streamline earlier stages of the CRC pathway.

Addressing Pressures in the Current Pathway

The NHS CRC pathway is under considerable strain. Currently:

  • Fewer than 55% of patients receive a formal diagnosis within the 28-day faster diagnosis standard.
  • The colonoscopy backlog exceeds 150,000 patients across the UK.

These challenges drive prolonged waiting times, increased patient anxiety, and elevated clinical and economic burden. Oricol™ PreView provides a practical mechanism to help relieve these pressures by enabling earlier stratification and more targeted use of endoscopy resources.

Demonstrating Acceleration in Real-World Deployment

The CDC pilot in Telford has shown the extent to which pathway performance can be improved when OriCol™ PreView is introduced upstream:

  • Patients can be assessed and provided with the test within 24 hours of first presentation
  • Test results are typically available within 47–72 hours, depending on laboratory workflow

This accelerated turnaround supports faster clinical decision-making, more appropriate prioritisation of colonoscopy capacity, and a smoother patient journey.

A Scalable Model for National Implementation

In collaboration with NHS innovation, Origin Sciences is preparing to replicate this model across 160 existing and 100 additionally planned CDCs. At full scale, this represents capacity for up to 1.7 million OriCol™ PreView tests annually, offering significant potential to improve diagnostic timelines, reduce downstream pressure on specialist service, and deliver tangible clinical and economic value.